Peripheral Nerve Stimulators Market Share

North America Market Statistics

North America peripheral nerve stimulators market is predicted to hold revenue share of more than 39.2% by 2037. The opioid crisis in North America has pushed healthcare providers and policymakers to prioritize non-opioid pain management strategies. PNS devices offer a safer alternative for chronic pain management without the risk of addiction, thereby driving their adoption across the region. Chronic pain, driven by conditions such as arthritis and neuropathy, is widespread in North America, boosting demand for peripheral nerve stimulators as non-pharmacological treatment options. In 2021, an estimated 20.9% of U.S. adults (51.6 million people) had chronic pain, and 6.9% (17.1 million people) had high-impact chronic pain, according to CDC data published in 2023.

The U.S. is embarking on significant growth in the peripheral nerve stimulators market due to favorable reimbursement policies. The U.S. healthcare system has increasingly embraced restitution for peripheral nerve stimulators, encouraging their adoption. Comprehensive insurance coverage for these devices makes them accessible to a broader patient base, boosting market growth. Furthermore, key players are developing advanced, cost-efficient peripheral nerve stimulators, driving innovation, and expanding their applications within the U.S. healthcare systems.

Canada peripheral nerve stimulators market is growing due to advancements in neuromodulation, including wireless, minimally invasive, and patient-specific devices that enhance treatment and convenience. These innovations attract healthcare providers and patients, while educational efforts boost awareness and adoption. In July 2022, Abbott received Health Canada licensing for NeuroSphere Virtual Clinic, a remote programming technology. This first-of-its-kind solution improves access to treatment for chronic pain, Parkinson’s, and essential tremors, especially for patients facing travel challenges.

APAC Market Analysis

In Asia Pacific, the peripheral nerve stimulators market is set to hold notable market figures over the forecast period. Asia Pacific is home to one of the fastest-growing elderly populations. Age-related diseases, including neuropathy and spinal cord disorders, contribute to chronic pain, making PNS devices an attractive solution for improving the quality of life for older adults. Governments in the Asia Pacific are implementing favorable reimbursement policies for pain management treatment, including PNS devices, making these therapies more accessible and promoting market growth.

China is projected to register a remarkable adoption rate in the peripheral nerve stimulators market. China is becoming a hub for medical tourism, attracting patients seeking advanced pain management treatments. The increasing number of international patients opting for PNS therapy in China further supports market expansion. Large population in China with chronic pain and neurological disorders is driving demand for effective pain management solutions, such as peripheral nerve stimulators (PNS), boosting market growth.

There has been a notable increase in awareness about advanced pain management therapies in India. Patients and healthcare providers are becoming more familiar with the benefits of PNS as a safe, effective alternative to opioid-based pain relief, which is contributing to the market’s growth. Further, ongoing innovations are driving the adoption of PNS devices in India, especially in urban centers with advanced healthcare facilities. According to a PIB article, published in November 2024, the medical devices industry was estimated to grow from USD 14.0 billion (2024) to USD 30.0 billion (2030). Thus, propagating the market.